Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Biocept Inc BIOCQ

Healthcare Biotechnology
Biocept, Inc. is a molecular oncology diagnostics company. The Company focuses on developing and commercializing clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor deoxyribonucleic acid (DNA) from blood and cerebrospinal fluid (CSF). Its product is branded and trademarked under the name CNSide. CNSide encompasses a suite of cellular and molecular... see more

Recent & Breaking News (GREY:BIOCQ)

Enrollment Completed in the Feasibility Phase of the FORESEE Clinical Trial with Biocept's CNSide(TM) Assay to Evaluate Patients with Leptomeningeal Metastases

Business Wire September 21, 2023

Biocept Signs CNSide(TM) Licensing Agreement with Plus Therapeutics

Business Wire September 8, 2023

Biocept to Participate in the H.C. Wainwright Global Investment Conference

Business Wire September 5, 2023

Biocept to Hold Business Update Conference Call on August 30, 2023

Business Wire August 25, 2023

Biocept Reports Second Quarter 2023 Financial Results

Business Wire August 14, 2023

Biocept's CNSide(TM) Cerebrospinal Fluid Assay Featured in Two Oral Presentations at the 2023 SNO/ASCO CNS Cancer Conference

Business Wire August 14, 2023

Biocept Announces the Passing of Board Chair M. Faye Wilson

Business Wire July 13, 2023

Biocept Names Antonino Morales as President and Chief Executive Officer

Business Wire June 20, 2023

Biocept to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 20, 2023

Business Wire June 14, 2023

Scientific Poster Presented at the 2023 ASCO Annual Meeting Highlights Performance of Biocept's CNSide(TM) Versus Cytology

Business Wire June 5, 2023

Biocept Announces Pricing of $5.0 Million Underwritten Public Offering

Business Wire May 24, 2023

Biocept Announces One-for-Thirty Reverse Stock Split

Business Wire May 17, 2023

Biocept Reports First Quarter 2023 Financial Results

Business Wire May 10, 2023

Biocept Reports 2022 Financial Results

Business Wire April 17, 2023

Enrollment Begins in FORESEE Clinical Trial Using Biocept's CNSide(TM) to Evaluate Patients with Leptomeningeal Metastases

Business Wire March 24, 2023

Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire March 1, 2023

Biocept to Explore Strategic Alternatives and Implement Restructuring Plan

Business Wire January 6, 2023

Biocept Reports Third Quarter 2022 Financial Results

Business Wire November 21, 2022

Biocept Appoints Financial Executive Quyen Dao-Haddock to its Board of Directors

Business Wire November 18, 2022

Biocept Announces Participation in an Investigator-Initiated Study to Better Understand the Development and Progression of Metastatic Breast Cancer to the Central Nervous System

Business Wire November 16, 2022